The new year has come, and Abbott Labs' (ABT 0.02%) spinoff of its branded pharmaceuticals division into the new company AbbVie (ABBV -0.48%) is complete. AbbVie is getting all of the attention from analysts at the moment because of its powerhouse arthritis drug, Humira, which generates the bulk of the revenue for the company -- but what about Abbott Labs? In this video, Motley Fool health care bureau chief Brenton Flynn tells us what he thinks of the trimmer new Abbott sans the branded pharmaceuticals, and why it reminds him a lot of Johnson & Johnson (JNJ 0.01%).
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What Should You Think of the New Abbott Labs?
NYSE: ABT
Abbott Laboratories

Now that Abbott Labs has slimmed down and lost its branded pharmaceuticals division by spinning off the new AbbVie, what should investors make of it?
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.